NEW YORK (GenomeWeb News) – Harvard Bioscience today reported that improved sales in the second quarter helped recude net loss by more than 98 percent.
 
Receipts for the three months ended June 30 increased 12 percent to $18 million from $16 million year over year as a result of improved product mix and higher margins on new product introductions, Harvard Bio said.
 
R&D costs increased 10 percent to $773,000 from $704,000 from the comparable quarter a year ago.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.